CTOs on the Move

Genesis Therapeutics

www.genesistherapeutics.ai

 
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Genesis Therapeutics raised $52M on 12/02/2020

Similar Companies

Abcuro

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1).

Novara Tesija Michela and Priehs

Novara Tesija Michela and Priehs is a Southfield, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

NewLeaf Symbiotics

NewLeaf Symbiotics® is at the forefront of sustainable agriculture technology, with a singular focus on the identification, development and commercialization of the beneficial microbes called pink pigmented facultative methylotrophs (M-trophs). This new class of agricultural microbes is helping transition agricultural products and production to deliver better quality crops, with less impact on the environment — a win-win for growers and those of us who depend on their success.

RuiYi

RuiYi is focused on the discovery and development of novel biologic therapeutics that have the potential to be disruptive globally. In addition to RYI-018 and RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company's technologies, including the iCAPS (intramembranous Conformation Antigen Presenting System). Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. RuiYi's executive management team has offices in La Jolla, California, and RuiYi's discovery efforts and research facility are located in in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, China.